- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|Advancing research through corporate and institutional partnerships|
NeuroNexus Technologies and Philips Research have signed a joint research agreement to develop next-generation deep brain stimulation devices with the ambition to improve the treatment of neurological diseases and psychiatric disorders. By combining Philips Research's strengths in microelectronics, signal processing, ultra-low power system design and miniaturization with NeuroNexus Technologies' expertise in micro-scale electrode design and fabrication, the two companies aim to show the technical feasibility of highly programmable and MRI-safe deep brain stimulation devices. Their initial research will aim to meet the functional requirements of a deep brain stimulation device for the treatment of Parkinson's disease. This is a degenerative disorder of the central nervous system that impairs people's motor skills and speech, leading to a progressive loss in quality of life. Recent publications suggest that deep brain stimulation could also be suitable for treating psychiatric disorders such as clinical depression.
Late-stage Parkinson's disease is increasingly being treated using deep brain stimulation - a technique that involves implantation of a medical device, a "brain pacemaker" that sends electrical impulses to specific parts of the patient's brain via permanently inserted electrodes. The pacemaker control unit is normally implanted into the patient's chest or abdomen, with a connecting lead routed under the skin to the brain electrode. While offering an effective therapy that helps many patients, currently available technologies have significant limitations.
"As currently used, deep brain stimulation poses several challenges to both the patient and the physician: The implantation requires a lengthy surgical procedure involving both neurosurgeons and neurologists. Following surgery, setting the right stimulation parameters requires painstaking efforts on the part of the neurologists before the patient can be sent home. In the long term, patients may for example develop spine problems that would require further examination using MRI, but with current implants MRI scans are not possible due to the materials used in the fabrication of DBS electrodes and the stimulators," explains Prof. Maximilian Mehdorn, Head of Neurosurgery at the Christian-Albrechts University of Kiel, Germany.
The joint research project aims to address these clinical needs, and will leverage Philips' expertise in medical imaging and surgery planning with the aim of simplifying the implantation process and shortening the surgical procedure. Philips will also contribute to making the entire device MRI compatible so that patients fitted with the implant are not barred from MRI scans. With its world-leading track record in neural micro-electrodes, NeuroNexus Technologies brings in key technology and knowledge for novel brain probes.
"As neuroscientists become increasingly able to understand the language of the brain and fix neurological conditions with advanced electrical stimulation techniques, they will need a new generation of DBS devices that give them much greater flexibility in tailoring therapy," explains Daryl Kipke, chief executive officer of NeuroNexus Technologies. "With our unique micro-scale implantable electrode technology and Philips Research's integration expertise, we are well positioned to make a significant leap forward in delivering technologies that will support neurologists and neurosurgeons in improving patient treatment."
"Contributing to the development of MRI-compatible deep brain stimulation devices may ultimately allow us to combine DBS technology with our functional imaging, image-guided intervention and therapy planning capabilities to produce integrated treatment suites for neurodegenerative disease," says Henk van Houten, senior vice president of Philips Research and head of its Healthcare Research program. "It's yet another example of where the coming together of in-depth clinical knowledge and world-class technology expertise can work to the benefit of patients."
Many Other Research Partnerships
Philips has also signed a long-term research partnership agreement with the West China Hospital, an affiliate of the Sichuan University in Chengdu, China. Under the seven-year agreement, Philips will collaborate with West China Hospital to develop new medical imaging procedures for the diagnosis and monitoring of certain types of cardiovascular disease (including coronary artery disease - one of the major diseases in China), cancer and mental diseases.
The Maastricht University Medical Centre (UMC+), University Medical Center Aachen (UKA) and Philips have signed a letter of intent to set up a strategic partnership, the aim of which is to pool their knowledge, expertise and experience in the field of healthcare. The planned cooperation will make it possible for new scientific findings to be made available more quickly for routine application in hospitals, thus benefiting patients. The universities of Aachen and Maastricht are also supporting the initiative.
Philips and the two university medical centers intend to work closely together and to combine their advanced clinical knowledge and research specifically in the fields of cardiovascular disease and cancer treatment. Their cooperation will cover the research, development and application of new diagnostic and treatment methods. Among other things, the partners' aim is to set up a joint research program in the field of medical imaging technology.
Philips and the University of Urbino (Urbino, Italy) have signed a research agreement to study the encapsulation of magnetic nanoparticle contrast agents inside living blood cells to prolong the retention time of these agents in the blood. Injected as free particles, magnetic nanoparticle contrast agents are quickly excreted from the blood via the patient's liver, which limits their application. During the collaboration, the University of Urbino will investigate the integration of magnetic nanoparticles into red blood cells and their biological interactions in the human body, while Philips Research will evaluate the properties of these contrast agents in its medical scanners. The collaboration between will last for approximately two and a half years, with expected initial applications in the treatment of cardiovascular disease - one of the biggest killers in the western world.
Philips has signed a memorandum of understanding (MoU) establishing a long-term research partnership with the University Medical Center (UMC) Utrecht, the Netherlands' largest university hospital. Philips and UMC Utrecht will seek to develop new solutions for the diagnosis, monitoring and treatment of major disease areas. Philips and UMC will develop collaborative research projects in medical imaging applied to brain disease, cancer, cardiovascular disease, musculoskeletal disease and pulmonary disease. A key area of focus outlined in the MoU is image guided oncology interventions. Philips and UMC Utrecht expect the agreement to result in new treatment methods that will ultimately lead to an improved quality of healthcare delivery.
Philips has signed a Memorandum of Understanding (MOU) for a five-year research collaboration with King's College London.Under the multi-million Euro agreement, Philips and King's College London's Division of Imaging Sciences will develop new medical imaging research projects with a particular focus on cardiology and cardiac electrophysiology. One of the key areas of focus will be on combining different imaging technologies, such as X-ray, MRI, ultrasound and CT, to help doctors navigate their way through a patient's heart during minimal-invasive procedures.
About NeuroNexus Technologies, Inc.
NeuroNexus Technologies, Inc. is a dynamic neurotechnology company providing advanced brain interface devices for neurological and scientific applications. The company's proprietary technology enables placement of sophisticated microelectronic and fluidic components on the surface of miniaturized brain probes that can be used to "map" brain function, to record or transmit information, to stimulate or modulate functions in specific regions where the brain's natural abilities to do so are compromised, or even to deliver drugs to precisely where they are needed. NeuroNexus is a leader in transforming ideas to technologies and technologies to innovative products by working at the leading-edge of science, technology, and clinical applications. NeuroNexus is based in Ann Arbor, Michigan USA. Additional information is located at www.NeuroNexusTech.com
The healthcare research alliance with NeuroNexus Technologies follows the recently announced partnerships with West China Hospital in China, the University Medical Centers of Maastricht (the Netherlands) and Aachen (Germany), and the University Medical Center Utrecht in the Netherlands, the University of Urbino (Italy) and King's College London (United Kingdom) and is part of Philips' increased commitment to developing solutions for improved patient care. A key success factor for this ambition is the effective translation from new concepts into clinical practice, which requires partnerships with leading academic, medical institutions and industrial partners. Bringing together such partnerships is one of the underlying principles behind Philips' policy of open innovation.
About Philips Research
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified Health and Well-being company, focused on improving people's lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 128,000 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare.
For more information, please click here
Copyright © Philips ResearchIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016
New theory could lead to new generation of energy friendly optoelectronics: Researchers at Queen's University Belfast and ETH Zurich, Switzerland, have created a new theoretical framework which could help physicists and device engineers design better optoelectronics August 23rd, 2016
Researchers watch catalysts at work August 19th, 2016